Workflow
医疗设备
icon
Search documents
无锡发布9项医疗惠民创新成果
Xin Hua Ri Bao· 2025-10-03 19:11
本报讯(记者马薇)9月30日,无锡市医疗健康"产医研融合"创新成果交流会举行,9项医疗卫生惠民便民 创新成果集中发布。 现场,无锡与国家癌症中心签署新一轮深化合作协议,共同深入开展全民癌症防控行动,探索肿瘤早诊 早治模式,通过早筛、早诊、早治无缝衔接,有效减轻社会医疗成本与家庭经济负担。2026年"医惠锡 城"新产品暨"一键e赔"功能上线,推出创新药械纳入保障、增加DRG除外责任等多项服务,进一步减轻 群众就医负担。一批高标准医疗康养设备在基层医疗卫生机构投放启用。据悉,今年,无锡计划向基层 医疗卫生机构投放10台高标准CT设备,向基层公办养老机构投放一批智能康养设备,让群众就医检查 更便利、康复养老更舒心。8家新一代互联网医院正式上线,将为市民提供升级版的"互联网+处方购 药""互联网+复诊""互联网+护理"服务。 会上,无锡市宣布新引进一批医学专家团队和高层次医疗卫生人才,成立药物临床试验机构联盟,并发 布2025年第一批生物医药创新产品目录。无锡市国联健康基金会正式揭牌,首期募集资金3000万元,用 于医学科研、人才培养和困难群体帮扶。同时,8家银行联合发布生物医药专项贷产品,首批为16家企 业提供综合 ...
AngioDynamics (ANGO) Reports Q1 Loss, Tops Revenue Estimates
ZACKS· 2025-10-02 12:11
Company Performance - AngioDynamics reported a quarterly loss of $0.1 per share, which was better than the Zacks Consensus Estimate of a loss of $0.14, representing an earnings surprise of +28.57% [1] - The company posted revenues of $75.71 million for the quarter ended August 2025, exceeding the Zacks Consensus Estimate by 4.75% and showing an increase from $67.49 million year-over-year [2] - Over the last four quarters, AngioDynamics has surpassed consensus EPS estimates four times and topped revenue estimates in the same period [2] Stock Movement and Outlook - AngioDynamics shares have increased approximately 20.9% since the beginning of the year, outperforming the S&P 500's gain of 14.1% [3] - The company's earnings outlook will be crucial for future stock performance, with current consensus EPS estimates at -$0.10 for the coming quarter and -$0.30 for the current fiscal year [4][7] - The current Zacks Rank for AngioDynamics is 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Instruments industry, to which AngioDynamics belongs, is currently in the top 35% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact AngioDynamics' stock performance [5]
云木长风CEO李思源解读企业估值偏差,访谈登陆美联社引国际关注
Sou Hu Cai Jing· 2025-09-30 11:56
近日,云木长风创始人兼CEO、资深营销专家李思源受邀参与行业深度访谈,围绕全球知名品牌咨询公 司Interbrand最新研究报告展开专业解读。该访谈已正式登陆美联社,引发国际商界与投资界对"企业估 值偏差"及"品牌资产价值"议题的广泛关注。访谈中,李思源结合十余年品牌战略实践经验,深入剖析 标普500指数中67%公司或存估值偏差的核心原因,提出系统性破局路径,其专业观点为全球企业优化 品牌价值传导、弥合估值差距提供重要参考。 美联社官网截图 访谈中一组数据引发热议:76%的投资分析师和财经记者认为品牌对企业市盈率(P/E)有显著影响, 但仅10%真正理解品牌定位与战略。李思源指出,这种"认知落差"加剧了估值偏差——医疗设备企业亨 利・谢因疫情后品牌复苏速度快于收入恢复却被低估,AlignTechnology在年轻群体中高品牌认知度未被 市场充分认可,均是典型案例。他进一步表示,许多企业投入大量资源建设品牌,却未能向投资界"翻 译"品牌价值,最终陷入"做而不宣、价值埋没"的困境,这一现象在其服务企业过程中尤为常见。 针对科技、医疗、金融三大行业的估值差异,李思源结合行业特性给出精准解读:科技行业易现"高价 值被 ...
开立医疗(300633)2025年中报点评:业绩逐季向好 新业务快速放量
Xin Lang Cai Jing· 2025-09-30 10:34
利润端:固定支出导致阶段性承压,同比增速呈现季度向好趋势。25H1 公司归母净利润同比增速 为-72.43%,下滑幅度超过收入同比增速,这主要与公司新产品线投入、研发及营销费用等固定支出较 大有关。分季度来看,25Q2 公司归母净利润同比增速为-44.65%,相较25Q1 的-91.94%已经有所改善, 呈现季度向好趋势,随着国内医疗设备行业市场需求的持续好转,预计公司业绩将逐步走出低谷期。 事项: 公司发布25 年中报,25H1,营业收入9.64 亿元(-4.78%),归母净利润0.47亿元(-72.43%),扣非净 利润0.40 亿元(-74.26%)。25Q2,营业收入5.34 亿元(+0.17%),归母净利润0.39 亿元 (-44.65%),扣非净利润0.34 亿元(-46.00%)。 评论: 收入端:国内业务阶段性承压,新业务快速放量。分地区来看,25H1 公司主营业务海外收入同比增速 为+0.33%,基本持平,主要原因系24H1 基数较高,公司海外业务整体表现稳健。25H1 公司主营业务 国内收入同比增速为-9.17%,虽然上半年国内医疗设备行业终端招标开始复苏,公司超声、内镜产品的 中标金额同 ...
宁德时代创历史新高,总市值超越茅台!硬科技宽基—双创龙头ETF(588330)拉升1.3%,2日连续吸金近4000万元
Xin Lang Ji Jin· 2025-09-30 06:33
今日(9月30日)上午,宁德时代A股总市值盘中再超贵州茅台。截至发稿,宁德时代总市值达18184亿 元,贵州茅台总市值达18090亿元。此前,9月25日盘中,宁德时代市值首次超越贵州茅台,创造了历史 性时刻。 市场分析人士表示,宁德时代总市值"稳超"贵州茅台或只是时间问题,A股市场"科技牛"信号已显现。 资本市场投资者用"真金白银"投票,正映射出中国产业经济的转型轨迹,"科技牛"的崛起已势不可挡。 中银证券认为,当前A股市场正呈现"科技结构性牛市",未来可能转入"全面牛"。这一判断基于科技产 业的强劲趋势和市场资金的重新配置。 业内人士指出,从中长期看,中国正经历新旧动能转换,科技创新和高端制造业将成为政策鼓励方向, AI、创新药等新兴产业有望形成"新叙事",推动具备科技属性的宽基指数持续受益。 盘面上,今日(9月30日)覆盖创业板+科创板高成长龙头的硬科技宽基——双创龙头ETF(588330)场 内价格盘中涨超1.3%,现涨0.11%,上探2021年8月以来的高点。上交所数据显示,双创龙头ETF (588330)近2日连续吸金,合计金额3914万元,或有资金逐步介入! 成份股方面,江波龙盘中20CM涨停,现 ...
迈瑞医疗涨2.03%,成交额12.31亿元,主力资金净流出442.85万元
Xin Lang Cai Jing· 2025-09-30 06:01
Core Viewpoint - Mindray Medical experienced a stock price increase of 2.03% on September 30, reaching 243.86 CNY per share, with a total market capitalization of 295.67 billion CNY [1] Financial Performance - For the first half of 2025, Mindray Medical reported a revenue of 16.743 billion CNY, a year-on-year decrease of 18.45%, and a net profit attributable to shareholders of 5.069 billion CNY, down 32.96% year-on-year [2] - Since its A-share listing, Mindray Medical has distributed a total of 33.699 billion CNY in dividends, with 23.388 billion CNY distributed over the past three years [3] Shareholder Information - As of June 30, 2025, the number of shareholders for Mindray Medical was 91,600, a decrease of 0.68% from the previous period, with an average of 13,241 circulating shares per person, an increase of 0.69% [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, holding 131 million shares, a decrease of 3.0252 million shares from the previous period [3]
招银证券:看好迈瑞医疗流水化业务成长,IVD流水线装机引领高端突破
Jiang Nan Shi Bao· 2025-09-30 04:12
Group 1 - The core trend in the medical device industry is the shift from single product sales to comprehensive solutions, with streamlined operations becoming a key driver for sustainable growth [1] - Mindray Medical (300760) leverages its strong R&D integration capabilities and full industry chain layout to deeply expand its streamlined operations in areas such as in vitro diagnostics (IVD), interventional treatment, and minimally invasive treatment [1][2] - The IVD business is central to Mindray's streamlined strategy, with plans to install over 200 new automated lines globally in 2024, and an expected increase to approximately 300 lines by 2025 [1][2] Group 2 - Mindray's core advantage lies in achieving comprehensive in-house production of multi-disciplinary assembly lines, significantly outperforming competitors in cost control and rapid iteration [2] - The company plans to launch iterative versions of the MT 8000 assembly line and compact assembly lines for grassroots hospitals and emergency scenarios between 2025 and 2026, further expanding market coverage [2] - Mindray aims to accelerate its catch-up with imported brands by adding at least 15 new chemiluminescence detection projects annually, focusing on key areas such as cardiac markers and hormone testing [2] Group 3 - In the interventional treatment sector, Mindray successfully replicates its streamlined model, expanding its business beyond cardiovascular intervention to include respiratory and urological departments, creating a comprehensive solution that includes treatment devices, navigation equipment, and consumables [2] - This "equipment + consumables" closed-loop model enhances customer value and strengthens business stability and sustainability [2] Group 4 - In the minimally invasive treatment field, Mindray is actively developing surgical robotics, aiming for world-class standards, which will enhance its comprehensive solution capabilities in high-end surgical areas [3] - The company's streamlined operations create a three-dimensional structure with IVD automation lines as the spearhead and interventional and minimally invasive treatments as the wings, generating stable revenue streams and smoothing out the cyclical fluctuations of single device sales [3] Group 5 - According to CMB Securities, Mindray has successfully built a resilient and growth-oriented business model through forward-looking layouts in streamlined operations, with rapid installations in IVD lines and ecosystem construction in interventional and minimally invasive fields expected to drive sustainable revenue growth [3] - Based on the positive momentum of the streamlined business, CMB Securities has slightly raised the company's profit expectations and maintained a "buy" rating [3]
奕瑞科技涨2.03%,成交额1.03亿元,主力资金净流出186.58万元
Xin Lang Cai Jing· 2025-09-30 03:20
Company Overview - Yirui Technology has seen a stock price increase of 71.14% year-to-date, with a 3.53% rise in the last five trading days, 2.09% in the last 20 days, and 31.42% in the last 60 days [2] - The company specializes in the research, production, sales, and service of digital X-ray detectors, with its main revenue sources being detector sales (81.21%), core component sales (7.66%), solution/technical service income (5.89%), accessory sales (4.57%), and rental income (0.66%) [2] - As of June 30, 2025, Yirui Technology reported a revenue of 1.067 billion yuan, a year-on-year increase of 3.94%, and a net profit attributable to shareholders of 335 million yuan, up 8.82% year-on-year [2] Market Performance - As of September 30, Yirui Technology's stock price was 115.65 yuan per share, with a market capitalization of 23.155 billion yuan [1] - The trading volume was 1.03 billion yuan, with a turnover rate of 0.45% [1] - The net outflow of main funds was 1.8658 million yuan, with large orders accounting for 23.21% of purchases and 24.90% of sales [1] Shareholder Information - Yirui Technology has distributed a total of 789 million yuan in dividends since its A-share listing, with 557 million yuan distributed over the past three years [3] - As of June 30, 2025, the number of shareholders increased by 21.67% to 6,990, with an average of 28,643 circulating shares per person, up 15.02% [2][3] - The ninth largest circulating shareholder is Huabao Zhongzheng Medical ETF, holding 3.926 million shares as a new shareholder [3]
瑞士医疗科技公司Hemotune研发血液磁性吸附珠,高效治疗败血症 | 瑞士创新100强
3 6 Ke· 2025-09-30 03:09
图源startupticker 瑞士医疗科技公司Hemotune成立于2017年,致力于研发血液磁性吸附珠。该吸附珠融合了生物医学和纳米技术,能够精准、直接地从患者血液中去除如毒 素、病原体或过量药物等致病物质,为败血症患者提供更具针对性、更高效的治疗方法。 Hemotune是苏黎世联邦理工学院的衍生公司,由Lukas Langenegger与Carlos Mora共同创立。Lukas Langenegger为公司首席执行官,拥有苏黎世联邦理工学 院化学和生物工程学士学位,曾在苏黎世联邦理工学院担任研究助理。Carlos Mora为公司首席技术官,拥有苏黎世联邦理工学院化学和生物工程博士学 位,曾在苏黎世联邦理工学院功能材料实验室担任研究员。 图源VentureLab 中毒、全身性感染或自身免疫性疾病均由致病因子在血液循环过程中引发。败血症是一种最严重的感染形式,又称血液中毒,是机体对细菌或病毒感染产生 的危及生命的异常免疫反应,其会通过血液传播的多种化合物导致免疫系统崩溃及器官损伤,最终引发多器官功能障碍,高达50%的脓毒性休克患者因此死 亡。败血症每年影响近5000万人,导致1100万人死亡。通常,最直接 ...
联影医疗涨2.01%,成交额3.38亿元,主力资金净流入1811.61万元
Xin Lang Cai Jing· 2025-09-30 02:30
联影医疗今年以来股价涨19.44%,近5个交易日涨4.86%,近20日涨0.21%,近60日涨18.04%。 资料显示,上海联影医疗科技股份有限公司位于上海市嘉定区城北路2258号,成立日期2011年3月21 日,上市日期2022年8月22日,公司主营业务涉及提供高性能医学影像设备、放射治疗产品、生命科学 仪器及医疗数字化、智能化解决方案。主营业务收入构成为:销售医学影像诊断设备及放射治疗设备 81.29%,提供维修收入13.56%,其他(补充)4.68%,软件收入0.47%。 联影医疗所属申万行业为:医药生物-医疗器械-医疗设备。所属概念板块包括:精准医疗、大盘、百元 股、基金重仓、融资融券等。 截至6月30日,联影医疗股东户数1.65万,较上期减少23.01%;人均流通股35953股,较上期增加 29.89%。2025年1月-6月,联影医疗实现营业收入60.16亿元,同比增长12.79%;归母净利润9.98亿元, 同比增长5.03%。 9月30日,联影医疗盘中上涨2.01%,截至10:11,报150.88元/股,成交3.38亿元,换手率0.27%,总市值 1243.49亿元。 资金流向方面,主力资金净流入 ...